Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + Cisplatin
Phase 1Active 2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic NSCLC
Conditions
Advanced or Metastatic NSCLC
Trial Timeline
Sep 15, 2020 → Apr 15, 2026
NCT ID
NCT04526691About Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + Cisplatin
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + Cisplatin is a phase 1 stage product being developed by Daiichi Sankyo for Advanced or Metastatic NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT04526691. Target conditions include Advanced or Metastatic NSCLC.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic NSCLC were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04526691 | Phase 1 | Active |
Competing Products
20 competing products in Advanced or Metastatic NSCLC